P-ISSN 2587-2400 | E-ISSN 2587-196X
Ejmo Kapak
EJMO Volume : 5 Issue : 2 Year : 2021
Ahead of Print | DOI: 10.14744/ejmo.2021.16863

MiR-19a Mediates Epithelial Mesenchymal Transition of Breast Cancer by Inhibiting KRAS

Xianchou Xu1, Peinan Wen2, Yinghao Wang3, Adheesh Bhandari3, Riyuan Zhang2, Shuqiang Shi2, Ouchen Wang3
1Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong, China, 2Department of general Surgery, The People’s Hospital of Pingyang, Wenzhou, Zhejiang, China, 3Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China,

It has been shown that microRNAs (miRNAs) provide functions that are necessary for quantities of biological processes in cancers. Epithelial to mesenchymal transition (EMT) plays a momentous role in the progression of malignant tumor cells metastasis. However, miR-19a has not been reported to be involved in EMT of breast cancer (BC). In this study, it was investigated that miR-19a was markedly reduced in BC clinical samples and cells. Ectopic expression of miR-19a blocked BC EMT. Mechanistic analyses indicated that kirsten rat sarcoma viral oncogene homolog (KRAS) was regulated by miR-19a directly. In addition, we showed that the overexpression of KRAS greatly attenuated the anti-invasive effect induced by miR-19a. This study sheds light on miR-19a inhibits BC cell EMT and invasiveness by targeting KRAS. Therefore, miR-19a and KRAS could be served as novel targets for BC biological therapy. Keywords: BC, miR-19a, EMT, KRAS


Cite This Article

Xu X, Wen P, Wang Y, Bhandari A, Zhang R, Shi S, et al. MiR-19a Mediates Epithelial Mesenchymal Transition of Breast Cancer by Inhibiting KRAS. EJMO. ; (): -

Corresponding Author: Ouchen Wang

EJMO & EJMO